Cargando…

Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin

BACKGROUND: Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, compared with placebo, reduced depressive symptoms in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berk, Michael, Mohebbi, Mohammadreza, Dean, Olivia M., Cotton, Sue M., Chanen, Andrew M., Dodd, Seetal, Ratheesh, Aswin, Amminger, G. Paul, Phelan, Mark, Weller, Amber, Mackinnon, Andrew, Giorlando, Francesco, Baird, Shelley, Incerti, Lisa, Brodie, Rachel E., Ferguson, Natalie O., Rice, Simon, Schäfer, Miriam R., Mullen, Edward, Hetrick, Sarah, Kerr, Melissa, Harrigan, Susy M., Quinn, Amelia L., Mazza, Catherine, McGorry, Patrick, Davey, Christopher G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966789/ https://www.ncbi.nlm.nih.gov/pubmed/31948461 http://dx.doi.org/10.1186/s12916-019-1475-6

Ejemplares similares

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial
por: Davey, Christopher G, et al.
Publicado: (2014)

O10.8. A PLURIPOTENTIAL AT RISK MENTAL STATE: INITIAL RESULTS
por: Hartmann, Jessica A, et al.
Publicado: (2018)

Bipolar At-Risk Criteria and Risk of Bipolar Disorder Over 10 or More Years
por: Ratheesh, Aswin, et al.
Publicado: (2023)

Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach
por: Hartmann, Jessica A., et al.
Publicado: (2021)

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
por: Cotton, S. M., et al.
Publicado: (2019)

Empirically driven transdiagnostic stages in the development of mood, anxiety and psychotic symptoms in a cohort of youth followed from birth
por: Ratheesh, Aswin, et al.
Publicado: (2023)

Cognitive ability and metabolic physical health in first-episode psychosis
por: Whitson, Sarah, et al.
Publicado: (2021)

Spine Wars: The Lessons of YODA
por: Chapman, Jens
Publicado: (2013)

Yoda1 analogue (Dooku1) which antagonizes Yoda1‐evoked activation of Piezo1 and aortic relaxation
por: Evans, Elizabeth L, et al.
Publicado: (2018)

Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
por: McGorry, Patrick D., et al.
Publicado: (2011)

ACTION OF SAHACHARADI YODA IN KHANJA AND PANGU
por: Nair, P. Ramachandran, et al.
Publicado: (1984)

Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial
por: Allott, Kelly, et al.
Publicado: (2023)

Recent Meta-Analyses in the Clinical High Risk for Psychosis Population: Clinical Interpretation of Findings and Suggestions for Future Research
por: Nelson, Barnaby, et al.
Publicado: (2018)

Heschl’s gyrus duplication pattern and clinical characteristics in borderline personality disorder: A preliminary study
por: Takahashi, Tsutomu, et al.
Publicado: (2022)

S130. INCIDENCE OF FIRST EPISODE OF PSYCHOSIS IN AN AUSTRALIAN COHORT AND ASSOCIATIONS WITH NEIGHBOURHOOD CHARACTERISTICS
por: Eaton, Scott, et al.
Publicado: (2018)

F130. INCREASED RISK OF PSYCHOTIC DISORDERS IN AFRICAN MIGRANTS TO AUSTRALIA
por: Downey, Linglee, et al.
Publicado: (2018)

The effectiveness of simple psychological and exercise interventions for high prevalence mental health problems in young people: a factorial randomised controlled trial
por: Parker, Alexandra G, et al.
Publicado: (2011)

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
por: Amminger, G P, et al.
Publicado: (2015)

Fine grained event processing on HPCs with the ATLAS Yoda system
por: Calafiura, Paolo, et al.
Publicado: (2015)

Fine grained event processing on HPCs with the ATLAS Yoda system
por: Calafiura, Paolo, et al.
Publicado: (2015)

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study
por: Amminger, G. Paul, et al.
Publicado: (2015)

T121. RATES AND PREDICTORS OF RELAPSE FOLLOWING DISCONTINUATION OF ANTIPSYCHOTIC MEDICATION AFTER A FIRST EPISODE OF PSYCHOSIS
por: Bowtell, Meghan, et al.
Publicado: (2018)

Commentary: Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
por: Nelson, Barnaby, et al.
Publicado: (2020)

Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept
por: Varadhan, Lakshminarayanan, et al.
Publicado: (2022)

Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study
por: Berger, M E, et al.
Publicado: (2017)

Online and Social Networking Interventions for the Treatment of Depression in Young People: A Systematic Review
por: Rice, Simon M, et al.
Publicado: (2014)

Probing the gating mechanism of the mechanosensitive channel Piezo1 with the small molecule Yoda1
por: Lacroix, Jerome J., et al.
Publicado: (2018)

Improving Mood with Physical ACTivity (IMPACT) trial: a cluster randomised controlled trial to determine the effectiveness of a brief physical activity behaviour change intervention on depressive symptoms in young people, compared with psychoeducation, in addition to routine clinical care within youth mental health services—a protocol study
por: Parker, Alexandra G., et al.
Publicado: (2019)

A mechanism for the activation of the mechanosensitive Piezo1 channel by the small molecule Yoda1
por: Botello-Smith, Wesley M., et al.
Publicado: (2019)

Overview and experience of the YODA Project with clinical trial data sharing after 5 years
por: Ross, Joseph S., et al.
Publicado: (2018)

Tubeimoside I Antagonizes Yoda1-Evoked Piezo1 Channel Activation
por: Liu, Silin, et al.
Publicado: (2020)

Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study
por: Kim, Sung-Wan, et al.
Publicado: (2016)

Speaker 3: Michael Berk, Australia
por: Michael, Berk, et al.
Publicado: (2016)

¡Yo soy yo! /
por: Lukela
Publicado: (2017)

Erythrocyte glutathione levels as long-term predictor of transition to psychosis
por: Lavoie, S, et al.
Publicado: (2017)

Yoda1 and phosphatidylserine exposure in red cells from patients with sickle cell anaemia
por: Wadud, R., et al.
Publicado: (2020)

Yoda1’s energetic footprint on Piezo1 channels and its modulation by voltage and temperature
por: Wijerathne, Tharaka D., et al.
Publicado: (2022)

PM396. Associations of obsessive–compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness
por: Kim, Sung-Wan, et al.
Publicado: (2016)

The Arabidopsis ANGUSTIFOLIA3-YODA Gene Cascade Induces Anthocyanin Accumulation by Regulating Sucrose Levels
por: Meng, Lai-Sheng, et al.
Publicado: (2016)

Using Yoda-1 to mimic laminar flow in vitro: A tool to simplify drug testing
por: Davies, Jessica E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9m9tkjod19mco77n6i481aep2f